JP2019527225A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527225A5 JP2019527225A5 JP2019503232A JP2019503232A JP2019527225A5 JP 2019527225 A5 JP2019527225 A5 JP 2019527225A5 JP 2019503232 A JP2019503232 A JP 2019503232A JP 2019503232 A JP2019503232 A JP 2019503232A JP 2019527225 A5 JP2019527225 A5 JP 2019527225A5
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- radiolabeled compound
- composition
- ido1
- radiolabeled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 12
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 11
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 11
- 239000012216 imaging agent Substances 0.000 claims 6
- 238000002600 positron emission tomography Methods 0.000 claims 6
- 238000001727 in vivo Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940043367 IDO1 inhibitor Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011503 in vivo imaging Methods 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364020P | 2016-07-19 | 2016-07-19 | |
| US62/364,020 | 2016-07-19 | ||
| PCT/US2017/042510 WO2018017529A1 (en) | 2016-07-19 | 2017-07-18 | Radioligands for imaging the ido1 enzyme |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527225A JP2019527225A (ja) | 2019-09-26 |
| JP2019527225A5 true JP2019527225A5 (enExample) | 2020-08-20 |
| JP6987840B2 JP6987840B2 (ja) | 2022-01-05 |
Family
ID=59416832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503232A Active JP6987840B2 (ja) | 2016-07-19 | 2017-07-18 | Ｉｄｏ１酵素イメージングのための放射性リガンド |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190282714A1 (enExample) |
| EP (1) | EP3487516A1 (enExample) |
| JP (1) | JP6987840B2 (enExample) |
| KR (1) | KR102513886B1 (enExample) |
| CN (1) | CN109475594A (enExample) |
| AU (1) | AU2017298262B2 (enExample) |
| BR (1) | BR112019000499A2 (enExample) |
| CA (1) | CA3031079A1 (enExample) |
| EA (1) | EA039877B1 (enExample) |
| IL (1) | IL264187B (enExample) |
| MX (1) | MX2019000508A (enExample) |
| SG (1) | SG11201900336YA (enExample) |
| WO (1) | WO2018017529A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019528300A (ja) * | 2016-08-26 | 2019-10-10 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法 |
| WO2019006292A1 (en) * | 2017-06-30 | 2019-01-03 | Bristol-Myers Squibb Company | SUBSTITUTED QUINOLINYCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED PROCESSES FOR THE PREPARATION THEREOF |
| KR20200088410A (ko) * | 2017-11-21 | 2020-07-22 | 광동 오포 모바일 텔레커뮤니케이션즈 코포레이션 리미티드 | 정보 전송 방법, 네트워크 디바이스 및 단말기 디바이스 |
| EP3720843A1 (en) * | 2017-12-05 | 2020-10-14 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| CN110357813A (zh) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 |
| AR120935A1 (es) * | 2020-01-02 | 2022-03-30 | Hutchison Medipharma Ltd | Derivados de amida y usos de los mismos |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101182359A (zh) * | 2007-11-09 | 2008-05-21 | 中山大学 | 人吲哚胺2,3-双加氧酶多克隆抗体及其制备方法和应用 |
| WO2011109262A2 (en) * | 2010-03-01 | 2011-09-09 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
| WO2016040458A2 (en) * | 2014-09-09 | 2016-03-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Pet probes of radiofluorinated carboximidamides for ido-targeted imaging |
| UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
-
2017
- 2017-07-18 EA EA201990198A patent/EA039877B1/ru unknown
- 2017-07-18 US US16/318,209 patent/US20190282714A1/en not_active Abandoned
- 2017-07-18 CN CN201780044908.4A patent/CN109475594A/zh active Pending
- 2017-07-18 KR KR1020197004720A patent/KR102513886B1/ko active Active
- 2017-07-18 SG SG11201900336YA patent/SG11201900336YA/en unknown
- 2017-07-18 BR BR112019000499-8A patent/BR112019000499A2/pt unknown
- 2017-07-18 AU AU2017298262A patent/AU2017298262B2/en active Active
- 2017-07-18 WO PCT/US2017/042510 patent/WO2018017529A1/en not_active Ceased
- 2017-07-18 MX MX2019000508A patent/MX2019000508A/es unknown
- 2017-07-18 CA CA3031079A patent/CA3031079A1/en active Pending
- 2017-07-18 EP EP17745597.9A patent/EP3487516A1/en active Pending
- 2017-07-18 JP JP2019503232A patent/JP6987840B2/ja active Active
-
2019
- 2019-01-10 IL IL264187A patent/IL264187B/en active IP Right Grant
-
2022
- 2022-04-18 US US17/722,628 patent/US20220305144A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527225A5 (enExample) | ||
| Flotats et al. | Hybrid cardiac imaging: SPECT/CT and PET/CT. A joint position statement by the European Association of Nuclear Medicine (EANM), the European Society of Cardiac Radiology (ESCR) and the European Council of Nuclear Cardiology (ECNC) | |
| JP2019520328A5 (enExample) | ||
| Yao et al. | Infection imaging with 18F-FDS and first-in-human evaluation | |
| Tatsumi et al. | Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18] fluoro-2-deoxy-D-glucose | |
| Gebhardt et al. | Dynamic behaviour of selected PET tracers in embryonated chicken eggs | |
| Cross et al. | Does PET-CT have a role in the evaluation of tuberculosis treatment in phase 2 clinical trials? | |
| Winkelmann et al. | Non-invasive MicroCT imaging characterization and in vivo targeting of BB2 receptor expression of a PC-3 bone metastasis model | |
| Conessa et al. | FDG-PET scan in local follow-up of irradiated head and neck squamous cell carcinomas | |
| US20230284994A1 (en) | Pet-ct imaging methods, contrast agents and pharmaceutical compositions for use in said imaging methods | |
| Greven | Positron-emission tomography for head and neck cancer | |
| JP2023536151A (ja) | 心筋画像化において［１８Ｆ］－Ｆ－ＡｒａＧを使用するための方法および材料 | |
| JPWO2020081410A5 (enExample) | ||
| JP2019001761A (ja) | 腫瘍イメージング剤、及びホウ素中性子捕捉療法用腫瘍治療剤 | |
| RU2405569C2 (ru) | Способ визуализации "сторожевых" лимфоузлов при раке гортани и гортаноглотки | |
| Singh et al. | 18F-FDG-PET SUV as a prognostic marker of increasing size in thyroid cancer tumors | |
| Yoo et al. | Monitoring of macrophage accumulation in statin-treated atherosclerotic mouse model using sodium iodide symporter imaging system | |
| Wang et al. | High-resolution dynamic imaging and quantitative analysis of lung cancer xenografts in nude mice using clinical PET/CT | |
| Airas et al. | In vivo positron emission tomography imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis | |
| Kang et al. | 18F-fluoride PET imaging in a nude rat model of bone metastasis from breast cancer: Comparison with 18F-FDG and bioluminescence imaging | |
| Han et al. | Clinical value of 18F-FDG PET/CT in postoperative monitoring for patients with colorectal carcinoma | |
| McCall et al. | [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments | |
| Boll et al. | Double-contrast micro-CT colonoscopy in live mice | |
| KR102369854B1 (ko) | C11-아세테이트를 유효성분으로 포함하는 성상교세포증 관련 질환의 병변 경계부 검출용 조영제 조성물 | |
| Greschus et al. | Non-invasive screening of lung nodules in mice comparing a novel volumetric computed tomography with a clinical multislice CT |